Zomedica Acquires UF Startup Structured Monitoring Products Adding Revolutionary VetGuardian Touchless Vital Signs Monitor to Product Portfolio
Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, announced it has completed the acquisition of UF startup Structured Monitoring Products, Inc., the makers of the VetGuardian touchless vital signs monitoring technology.
President Sasse Begins Yearlong Strategic Planning Process
Sustainable research expenditure growth, effective post-tenure review, recruiting even more top-flight faculty, and establishing even greater impact beyond Gainesville are all part of University of Florida President Ben Sasse’s far-reaching vision for UF as he launches a yearlong strategic planning process to chart UF’s course for the next decade.
UF Research Spending Up 15% to Record $1.25 Billion
University of Florida faculty conducted a record $1.25 billion in research in fiscal year 2023, a nearly 15% increase over 2022.
NCI Grant Funds Study of Anti-Cancer Drugs to Treat Aggressive Breast Cancer
A University of Florida Health Cancer Center researcher has received a two-year $400,000 grant from the National Cancer Institute to evaluate a new class of anti-cancer drugs to treat aggressive types of breast cancer.
Tech Tuesday: Eufinity
This week’s Tech Tuesday introduces us to Eufinity, which offers a text-message app designed to make mental health care accessible and stigma-free for college students.
UF/IFAS Research: On the Verge of Developing a Domestic Industry for One of the World’s Most Valuable Spices
University of Florida researchers in Homestead are on the verge of developing a domestic vanilla industry, poised to transform agriculture in Florida, Puerto Rico, and the U.S. Virgin Islands for interested small growers and investors.
UF Researcher to Study Strategies to Restore and Rejuvenate Blood Cells
With a $2.6 million four-year grant from the National Heart Lung and Blood Institute, a University of Florida Health Cancer Center researcher will study strategies to restore the function of aging blood vessels and stem cells, with the long-term goal of improving treatments for diseases such as blood cancers.
Atsena Therapeutics Doses First Patient in Phase I/II Clinical Trial of ATSN-201 for Treatment of X-Linked Retinoschisis
Atsena Therapeutics announced the first patient has been dosed in its Phase I/II clinical trial, the LIGHTHOUSE study, evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
UF Researchers Create Powerful Cancer-Targeting Compound
A team of University of Florida medicinal chemists and cancer biologists has created a chemical compound that powerfully and selectively helped cells dispose of proteins that cause cancer cells to grow.
Tech Tuesday: Sinmat
From smartphones to medical equipment, microchips improve technologies and transform – even save – our lives. The technology -- and the company, Sinmat -- featured in today’s Tech Tuesday makes advanced microchips possible.
